David Rosmarin MD
Instructor in Dermatology, Brigham and Women's Hospital
Join to View Full Profile
550 University BlvdSte 3240Indianapolis, IN 46202
Phone+1 317-948-8657
Fax+1 317-944-7051
Dr. Rosmarin is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Boston University Medical CenterResidency, Dermatology, 2006 - 2009
New York Presbyterian Hospital (Cornell Campus)Internship, Internal Medicine, 2005 - 2006
New York University School of MedicineClass of 2005
Certifications & Licensure
IN State Medical License 2022 - 2027
MA State Medical License 2008 - 2023
NY State Medical License 2013 - 2016
American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks, eClinicalWorks, LLC, 2014-2016
- CMS Meaningful Use Stage 2 Certification eClinicalWorks, eClinicalWorks, LLC, 2014-2016
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2013
Clinical Trials
- A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis Start of enrollment: 2016 Apr 01
- Topical Ruxolitinib for the Treatment of Vitiligo Start of enrollment: 2016 Jan 01
- Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa Start of enrollment: 2016 Jul 11
Publications & Presentations
PubMed
- Brief Report: Shorter Lead Time for New Patient Appointments Improves No-Show Rates in Dermatology Clinics.Alison Klenk, David J Gunderman, Callie B Burgin, Janelle S Nassim, Edita Newton
Journal of the American Academy of Dermatology. 2026-06-24 - Clinical Characteristics and Treatment Patterns in Patients With Vitiligo.Roni Adiri, Genevieve Gauthier, Samantha K Kurosky, Mojgan Sadrarhami, Griffith Bell
JAMA Dermatology. 2026-05-06 - Impact of treatment duration on response durability: A post hoc analysis of the double-blind, vehicle-controlled, randomized TRuE-V long-term extension study of ruxoli...David Rosmarin, Thierry Passeron, José L López-Estebaranz, Haobo Ren, Abdelhak Amara Korba
Journal of the American Academy of Dermatology. 2026-04-14
Press Mentions
Adolescents with Vitiligo Achieve Higher Repigmentation Rates with Topical Ruxolitinib Than AdultsJuly 16th, 2024- Seeing Red with DupilumabMarch 1st, 2023
- NEJM Publishes Tufts' Study of Skin Repigmentation Treatment for VitiligoOctober 20th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
